机译:Natalizumab(Tysabri?)的II期试验与皮质类固醇作为胃肠道急性移植物与宿主病的初始治疗
The Ottawa Hospital Research Institute;
Department of Biostatistics and Computational Biology Dana-Farber Cancer Institute;
Division of Hematologic Malignancies Dana-Farber Cancer Institute;
Dana Farber Cancer Institute;
Dana Farber Cancer Institute;
Dana Farber Cancer Institute;
Division of Hematologic Malignancies Dana-Farber Cancer Institute;
Division of Hematologic Malignancies Dana-Farber Cancer Institute;
Division of Hematologic Malignancies Dana-Farber Cancer Institute;
Hematologic Malignancies Dana-Farber Cancer Institute Harvard Medical School;
Dana-Farber Cancer Institute;
Hematologic Malignancies Dana-Farber Cancer Institute Harvard Medical School;
Hematology/Oncology Massachusetts General Hospital Harvard Medical School;
Hematologic Malignancies Dana-Farber Cancer Institute Harvard Medical School;
Division of Hematologic Malignancies Dana-Farber Cancer Institute;
Blood and Marrow Transplant Program Massachusetts General Hospital;
Dana-Farber Cancer Institute;
机译:None
机译:矫正:Natalizumab的II期试验与皮质类固醇作为胃肠道急性移植物与宿主病的初步治疗。
机译:纳莱替努亚与皮质类固醇的第二阶段试验作为胃肠急性移植物与宿主疾病的初始治疗。
机译:抗胸腺细胞球蛋白(ATG-Fresenius)预防无关供体骨髓移植的小儿和成年患者的急性和慢性移植物抗宿主病
机译:魔术算法概率(地图)是急性接枝腹膜疾病治疗的验证响应生物标志物
机译:用于急性接枝与宿主疾病初始治疗初始治疗的III期研究
机译:英夫利昔单抗和糖皮质激素用于急性移植物抗宿主病的初始治疗的III期研究